Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856315 | 0.95 | NPSR1 (0.58) | NPSR1ALDH1A1SMN1; SMN2CACNA1GKMT2A | |
| SCHEMBL2856685 | 0.90 | NPSR1 (0.49) | NPSR1ALDH1A1CACNA1GKMT2AMEN1 | |
| SCHEMBL2867646 | 0.87 | ALDH1A1 (0.45) | NPSR1ALDH1A1SMN1; SMN2CACNA1GTP53 | |
| SCHEMBL2870790 | 0.86 | NPSR1 (0.48) | NPSR1ALDH1A1CACNA1GKMT2AMEN1 | |
| SCHEMBL2871764 | 0.86 | NPSR1 (0.48) | NPSR1ALDH1A1SMN1; SMN2TP53KMT2A | |
| SCHEMBL2861757 | 0.85 | NPSR1 (0.47) | NPSR1ALDH1A1KMT2AP2RX7 | |
| SCHEMBL2858851 | 0.85 | NPSR1 (0.47) | NPSR1ALDH1A1CACNA1GP2RX7 | |
| SCHEMBL2865680 | 0.83 | NPSR1 (0.46) | NPSR1ALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL2863305 | 0.83 | NPSR1 (0.45) | NPSR1ALDH1A1 | |
| SCHEMBL2860583 | 0.82 | NPSR1 (0.44) | NPSR1ALDH1A1KMT2AMEN1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885ALDH1A1 2926/4885SMN1; SMN2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.